Price T Rowe Associates Inc. MD Purchases New Shares in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Price T Rowe Associates Inc. MD purchased a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the 4th quarter, Holdings Channel reports. The fund purchased 10,425 shares of the company’s stock, valued at approximately $69,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Barclays PLC raised its holdings in Lexeo Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after buying an additional 31,057 shares during the period. Wellington Management Group LLP increased its stake in Lexeo Therapeutics by 48.3% in the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after purchasing an additional 25,089 shares during the period. Rhumbline Advisers increased its stake in Lexeo Therapeutics by 19.6% in the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock worth $166,000 after purchasing an additional 4,127 shares during the period. JPMorgan Chase & Co. increased its stake in Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after purchasing an additional 5,915 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Lexeo Therapeutics in the fourth quarter worth $117,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Up 20.0%

NASDAQ:LXEO opened at $3.24 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $19.50. The company has a 50-day moving average of $3.07 and a 200 day moving average of $4.92. The firm has a market cap of $107.56 million, a PE ratio of -1.03 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.19). As a group, research analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LXEO. Chardan Capital reduced their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Royal Bank of Canada reduced their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reduced their target price on Lexeo Therapeutics from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Leerink Partners reduced their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.20.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.